Invention Grant
US08389474B1 Rationale for IL-1 β targeted therapy to improve harvested organ viability, allograft tolerance, replant success and for conditions characterized by reduced or absent arterial perfusion
失效
IL-1和bgr的理由 靶向治疗以改善收获的器官活力，同种异体移植耐受性，复发成功和特征为减少或缺乏动脉灌注的病症
- Patent Title: Rationale for IL-1 β targeted therapy to improve harvested organ viability, allograft tolerance, replant success and for conditions characterized by reduced or absent arterial perfusion
- Patent Title (中): IL-1和bgr的理由 靶向治疗以改善收获的器官活力，同种异体移植耐受性，复发成功和特征为减少或缺乏动脉灌注的病症
-
Application No.: US12803920Application Date: 2010-07-09
-
Publication No.: US08389474B1Publication Date: 2013-03-05
- Inventor: Alan Anson Wanderer
- Applicant: Alan Anson Wanderer
- Main IPC: A61K38/00
- IPC: A61K38/00 ; A61K39/00
Abstract:
Ischemia-reperfusion (IR) injury involving harvested organs and allograft transplantation may be increased by stimulation of a newly described innate pro-inflammatory immune system (i.e.NALP-3-inflammasome) which can cause secretion of IL-1β and subsequent neutrophilic inflammation. Ischemia and hypoxia can cause metabolic acidosis and development of danger signals known to stimulate IL-1β secretion from the NALP-3 inflammasome. Based on this newly discovered mechanism causing pathobiology in IRI, IL-1β targeted therapy would be capable of improving allograft tolerance, viability of harvested organs and in conditions with compromised arterial blood supply and subsequent reperfusion, such as replants, compartment syndrome, and serious vascular accidents.
Information query
IPC分类:
